- Home
- KOD vs TVGN Comparison
KOD vs TVGN Comparison
Compare KOD & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- TVGN
- Stock Information
- Founded
- KOD 2009
- TVGN 2020
- Country
- KOD United States
- TVGN United States
- Employees
- KOD N/A
- TVGN N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- TVGN Blank Checks
- Sector
- KOD Health Care
- TVGN Finance
- Exchange
- KOD Nasdaq
- TVGN Nasdaq
- Market Cap
- KOD 188.9M
- TVGN 193.1M
- IPO Year
- KOD 2018
- TVGN N/A
- Fundamental
- Price
- KOD $3.67
- TVGN $1.24
- Analyst Decision
- KOD Hold
- TVGN Strong Buy
- Analyst Count
- KOD 3
- TVGN 1
- Target Price
- KOD $9.00
- TVGN $10.00
- AVG Volume (30 Days)
- KOD 292.9K
- TVGN 734.5K
- Earning Date
- KOD 08-13-2025
- TVGN 08-13-2025
- Dividend Yield
- KOD N/A
- TVGN N/A
- EPS Growth
- KOD N/A
- TVGN N/A
- EPS
- KOD N/A
- TVGN N/A
- Revenue
- KOD N/A
- TVGN N/A
- Revenue This Year
- KOD N/A
- TVGN N/A
- Revenue Next Year
- KOD N/A
- TVGN N/A
- P/E Ratio
- KOD N/A
- TVGN N/A
- Revenue Growth
- KOD N/A
- TVGN N/A
- 52 Week Low
- KOD $1.92
- TVGN $0.26
- 52 Week High
- KOD $11.60
- TVGN $3.09
- Technical
- Relative Strength Index (RSI)
- KOD 51.01
- TVGN 52.07
- Support Level
- KOD $3.55
- TVGN $1.14
- Resistance Level
- KOD $3.82
- TVGN $1.22
- Average True Range (ATR)
- KOD 0.30
- TVGN 0.09
- MACD
- KOD -0.02
- TVGN -0.01
- Stochastic Oscillator
- KOD 35.00
- TVGN 44.12
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.